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Summary
The aim of this study was to determine the genetic regulation of macrophage
migration inhibitory factor (MIF).DNase I hypersensitivity was used to iden-
tify potential hypersensitive sites (HS) across the MIF gene locus. Reporter
gene assays were performed in different human cell lines with constructs
containing the native or mutated HS element. Following phylogenetic and
transcription factor binding proﬁling, electrophoretic mobility shift assay
(EMSA) and RNA interference were performed and the effects of incubation
with mithramycin, an antibiotic that binds GC boxes, were also studied. An
HS centred on the ﬁrst intron of MIF was identiﬁed. The HS acted as an
enhancer in human T lymphoblasts (CEMC7A), human embryonic kidney
cells (HEK293T) and human monocytic cells (THP-1),but not in a ﬁbroblast-
like synoviocyte (FLS) cell line (SW982) or cultured FLS derived from rheu-
matoid arthritis (RA) patients. Two cis-elements within the ﬁrst intron were
found to be responsible for the enhancer activity. Mutation of the consensus
S p 1G Cb o xo ne a c hcis-element abrogated enhancer activity and EMSA indi-
cated Sp1 binding to one of the cis-elements contained in the intron. SiRNA
knock-downof Sp1aloneorSp1andSp3togetherwasincompleteanddidnot
alter the enhancer activity. Mithramycin inhibited expression of MIF in
CEMC7A cells. This effect was speciﬁc to the intronic enhancer and was not
seen on the MIF promoter. These results identify a novel, cell type-speciﬁc
enhancer of MIF. The enhancer appears to be driven by Sp1 or related Sp
family members and is highly sensitive to inhibition via mithramycin.
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Introduction
Macrophage migration inhibitory factor (MIF) is an early
modulator of inﬂammation and is active in both innate and
adaptive immunity [1–3].Although its role as a direct cytok-
ine is not entirely resolved [4],the case for MIF as an impor-
tant modulator of inﬂammation is increasingly strong.
Rheumatoidarthritis(RA)isachronicinﬂammatorydisease
of unknown aetiology affecting ~ 1% of the world’s
population. It is characterized by progressive destruction of
synovialjoints.Asubstantialbodyof evidencesupportsakey
role for MIF in RA.Multiple different animal models show a
role of MIF in the inﬂammatory joint process [5–9]. Fur-
thermore, elevated levels of MIF have been shown in RA
synovial ﬂuid and serum samples, compared to healthy and
osteoarthritic controls [10,11]. MIF stimulates macrophage
release of tumour necrosis factor (TNF)-a, interleukin
(IL)-1,IL-6 and IL-8,all of which occur at increased levels in
RA patients. RA ﬁbroblast-like synoviocyte (FLS)-derived
MIF induces monocyte TNF-a production in vitro [10],and
MIF up-regulates FLS IL-1 mRNA expression [12]. In addi-
tion to MIF’s role as a potential upstream regulator of syn-
ovial cytokine expression, MIF contributes to the processes
involved in synovial joint destruction: MIF induces metallo-
proteinases (MMP)-1 (interstitial collagenase) and MMP-3
(stromelysin) in FLS [12]. Murine osteoblasts express high
levels of MIF [13]. MIF stimulates MMP-9 (gelatinase B)
and MMP-13 (collagenase 3) from rat calvarial osteoblasts
[13] and RA FLS induction of MMP-2 by MIF has also
been described [14]. MIF-DNA vaccine protects from
ovariectomy-induced bone loss [15] and MIF transgenic
mice have high turnover osteoporosis associated with
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work supports the involvement of MIF in the cartilage
damage and bone remodelling that is central to the progres-
sive joint destruction that occurs in RA.
MIF has an unusual relationship with glucocorticoids
(Gc) acting as a counter-regulator as well as being found, in
some studies, to be induced by them [7,17–20]. Despite the
use of new biological disease-modifying drugs, more than
half of patients with RA are treated with Gc [18]. The meta-
bolic side effects of Gc cause considerable morbidity, espe-
cially with long-term use, as occurs in RA. Steroid-sparing
therapies, such as those that limit elevation of MIF expres-
sion, would therefore be clinically advantageous.
The MIF gene is situated on chromosome 22q11.2 within
a cytosine–guanine–dinucleotide (CpG) island,and is highly
conserved(90%)betweenmammalianspecies[21].TheMIF
promoter is GC-rich and has no TATA box, suggesting the
presence of other regulatory elements. Despite MIF being a
key modulator of RA aetiopathogenesis, little is currently
knownaboutMIFgeneregulation.Baughet al.[22],Welford
et al.[23] and Elsby [24] have shown MIF to be regulated via
the hypoxia inducible transcription factor (HIF-1), and pre-
vious work found regulation of the proximal MIF promoter
by cyclic AMP response element binding protein [25].There
is also evidence demonstrating the cell type-speciﬁc inhibi-
tion of MIF gene expression by Gc [20]. Importantly, MIF,
unlike other proinﬂammatory mediators,is not regulated by
TNF-a [24]. The aim of this study was therefore to identify
functional regulatory elements for the MIF gene,so allowing
identiﬁcation of factors important in the control of MIF
expression. Using an unbiased DNase I hypersensitivity
approach, we have identiﬁed a novel cell type-speciﬁc
enhancer within the ﬁrst intron of MIF. Further character-
ization of the enhancer demonstrated that it was physiologi-
cally relevant and that regulation of the enhancer with the
antibiotic mithramycin resulted in repression of MIF
expression.
Materials and methods
Cell lines
CEMC7A, a human T lymphoblast cell line, THP-1, a
monocytic cell line and RA FLS were cultured in RPMI-
1640 (Gibco PRL, Paisley, UK) with 10% fetal bovine
serum (FBS) (PerBio; Sigma, Poole, UK). RA FLS were iso-
lated and cultured as described previously [10] and used
between passages 4 and 8. The human ﬁbroblast-like syn-
oviocytes cell line (SW982) was cultured in l–15 Leibovitch
(Gibco) with 10% FBS. Human lung carcinoma cells
(A549) and kidney cells (HEK293T) were cultured in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) with Glutamax
(Gibco) with 10% FBS (PerBio).All cell lines were grown in
a 37°C incubator with 5% CO2. THP-1, A549, HEK293T
and SW982 were obtained from the American Type Culture
Collection (ATCC); CEMC7A was kindly provided by Dr
Ged Brady.
Generation of probes
All polymerase chain reactions (PCR) were performed on
a PTC-0225 DNA Engine Tetrad Thermal cycler (MJ
Research, Waltham, MA, USA). Sequence for the probe was
acquired via a search for MIF DNA on the UCSC Genome
Bioinformatics website (http://genome.ucsc.edu/).Sequence
was veriﬁed for speciﬁcity using blast on the National
Center for Biotechnology Information (NCBI) website
(http://www.ncbi.nlm.nih.gov/BLAST/) and a 465 base pairs
(bp) sequence was chosen to target the 5′ end of the 10·2 Kb
DNA fragment containing the MIF gene. This fragment was
generated by BglII restriction digest of human genomic
DNA. The probe was generated by PCR forward: 5′-GGAG
GTAAGGGGTCAGGAGG-3′,p r o b e4r e v e r s e5 ′-GTGTTCA
CCTGACATAGAGG-3′ primers. The PCR product was then
cloned into pCR®4Blunt-TOPO (Invitrogen, Paisley, UK).
Probesequencewasconﬁrmedbysequencingusingthesame
primer as for PCR.
DNase I hypersensitivity assay
Conﬂuent cells (~10
8 cells) were washed four times with cold
phosphate-bufferedsaline(PBS)andthenpelleted.Cellswere
lysed in 20 ml 1¥ reticulocyte standard buffer (RSB) buffer
(10 mM Tris pH7·4, 10 mM NaCl, 3 mM MgCl2) with 0·1%
NP-40 for 7–10 min and the nuclei pelleted. Nuclei were
washed in 20 ml of 1¥ RSB only, pelleted at 783 g for 5 min
and resuspended in a ﬁnal volume of 1 ml of 1¥ RSB.Differ-
ent concentrations of DNase I (Worthington,Lakewood,NJ,
USA)wereaddedtoeachtube(0,0·3,1,3,10,30and100 mg/
ml) and incubated at 37°C for 10 min. DNA samples were
stored immediately at -20°C or puriﬁed with DNeasy
columns (Qiagen, Crawley, UK) as per the manufacturer’s
instructions. Ten mg of each isolated DNA sample was
digested with Bgl II (Roche, Burgess Hill, UK) at 37°C over-
night. Samples were then run on agarose or stored at 4°C.
Southern blotting
DNA was resolved on 0·8% 1¥ Tris–borate–ethylenediamine
tetraacetic acid (EDTA) (TBE) agarose and transferred onto
Hybond
+ membrane (Amersham, Little Chalfont, Bucking-
hamshire,UK).Probeswerelabelledwith[a-
32P]dCTPusing
Random Primers DNA Labelling System (Invitrogen)
according to the manufacturer’s instructions. Labelled DNA
was cleaned up using a microspin G50 column (Amersham),
boiled for 5 min, then added to the prehybridization buffer
and left to hybridize overnight at 65°C. Membranes were
then washed twice for a minimum of 10 min in 2¥ saline
sodium citrate (SSC), 0·1% sodium dodecyl sulphide (SDS)
at 65°C and autoradiography performed.
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The whole of MIF intron 1 (194 bp) was ampliﬁed by PCR
using the following primers: forward primer 5′-GGATCCG
CGGGTCTCCTGGTCCTTCT-3′ and reverse primer 5′-
GGATCCCGCGATGTACTGCGAGGAAAG-3′. The ampli-
cons were cloned initially into pBLUNT vector (Invitrogen),
subcloned into pGL3-promoter vector (Promega,
Southampton, UK) and then sequenced, and for each con-
struct a clone with the intron in the sense (S) or anti-sense
(AS) orientation was isolated.These were digested with XhoI
and HindIII to open up the promoter site and replace the
SV40 promoter with the MIF promoter region. MIF pro-
moter was obtained by digesting the pGL3-enhancer/MIF
CATT promoter construct described previously [20] with
XhoI and HindIII. The gel-puriﬁed promoter was then
ligated into pGL3-promoter/intron wild-type (WT) S,
pGL3-promoter/intron WT AS, pGL3-promoter/intron
single nucleotide polymorphism (SNP) S and pGL3-
promoter/intron SNP AS using the XhoI and HindIII sites.
Tiled oligonucleotide constructs
Overlapping WT (Metabion, Martinsried, Germany) or
mutated oligonucleotides (Invitrogen), each ~50 bp and
spanning the whole of MIF intron 1 (oligo-1–oligo-7), were
designed and phosphorylated at the 5′ end. The sequences
are given in Table 1. Complementary oligonucleotides were
annealed and ligated into the pGL3 promoter vector using
the BamHI sites. All plasmids were sequenced.
Transfection of plasmid DNA
Cells were transfected transiently in triplicate using either
electroporation, Lipofectamine 2000 (Invitrogen) or
nucleofection. For electroporation, CEMC7A and THP-1
cells were resuspended in serum-free medium at 10
7 cells per
ml. Plasmid DNA (10 mg) was added with renilla (1 mg) as
transfection efﬁciency control.Lipofectamine 2000 was used
for SW982, HEK293T and CEMC7A cells. Plasmid DNA
(0·2–1·5 mg) and renilla control (0·2–0·8 mg) were used for
each transfection in a 96-well or a 24-well plate. HEK293T
and SW982 were seeded at 2 ¥ 10
5 cells/ml and CEM cells at
5 ¥ 10
5 cells/ml to 3 ¥ 10
6 cells/ml and left to grow overnight.
Transfections were performed as per the manufacturer’s
instructions. For nucleofection, CEMC7A were resuspended
in medium at 5 ¥ 10
6 cells/ml and grown overnight. Using
the nucleofector KitV,a total of 1 ¥ 10
6 cells/ml was used per
reaction to co-transfect siRNA with plasmid DNA with the
program C16. For human RA FLS, a total of 0·5 ¥ 10
6 cells
were used per reaction to transfect 2·5 mg of plasmid DNA
with the program U23 using the nucleofection kit for NHLF
(Amaxa, Wokingham, Berkshire, UK). Transfections were
performed according to the manufacturer’s protocol.
All luciferase/renilla assays were performed 24 h post-
transfection as described previously, and the normalized
luciferase data presented [26].
SP1 knock-down
A pool of four siRNA sequences directed against Sp1
(M-026959-00 siGENOME SMARTpool reagent; Dharma-
con, Lafayette, CO, USA) or lamin A/C control (D-001620-
02-05 siGLO lamin A/C; Dharmacon) as a negative control
were co-transfected with plasmid DNA (SV40/MIF intron
WT S and SV40 promo) in HEK293T and CEMC7A,accord-
ing to the manufacturer’s instructions. Transfections were
performedin24-wellplatesbynucleofectionforCEMC7Aor
using Lipofectamine 2000 (Invitrogen) for HEK293T. iRNA
(100 nM) and plasmid DNA (1–5 mg) were transfected, cells
Table 1. Tiled ~50 base pairs overlapping oligonucleotide constructs designed across migration inhibitory factor (MIF) intron 1.
oligo1 5′-GATCCGTTTGCCGGGAGGGGACAGGAAGAGGGGGGTGCCCACCGGG-3′
oligo1comp 5′-TCGACCCGGTGGGCACCCCCCTCTTCCTGTCCCCTCCCGGCAAACG-3′
oligo2 5′-GATCCGGGGGTGCCCACCGGACGAGGGGTTCCGCGCTGGGAGCTGG-3′
oligo2comp 5′-TCGACCAGCTCCCAGCGCGGAACCCCTCGTCCGGTGGGCACCCCCG-3′
oligo3 5′-GATCCCCGCGCTGGGAGCTGGGGAGGCGACTCCTGAACGGAGCTGG-3′
oligo3comp 5′-TCGACCAGCTCCGTTCAGGAGTCGCCTCCCCAGCTCCCAGCGCGGG-3′
oligo4 5′-GATCCAACGGAGCTGGGGGGCGGGGCGGGGGGAGGACGGTGGCTCG-3′
oligo4comp 5′-TCGACGAGCCACCGTCCTCCCCCCGCCCCGCCCCCCAGCTCCGTTG 3-3′
oligo5 5′-GATCCACGGTGGCTCGGGCCCGAAGTGGACGTTCGGGGCCCGACGG-3′
oligo5comp 5′-TCGACCGTCGGGCCCCGAACGTCCACTTCGGGCCCGAGCCACCGTG-3′
oligo6 5′-GATCCGTTCGGGGCCCGACGAGGTCGCTGGGGCGGGCTG-3′
oligo6comp 5′-TCGACAGCCCGCCCCAGCGACCTCGTCGGGCCCCGAACG-3′
oligo7 5′-GATCCTCGCTGGGGCGGGCTGACCGCGCCCTTTCCTCGCAGG-3′
oligo7comp 5′-TCGACCTGCGAGGAAAGGGCGCGGTCAGCCCGCCCCAGCGAG-3′
oligo1mut 5′-GATCCGTTTGCCTTGAGGTGACAGGAAGAGGGGGGTGCCCACCGGG-3′
oligo1mutcomp 5′-TCGACCCGGTGGGCACCCCCCTCTTCCTGTCACCTCAAGGCAAACG-3′
oligo6mut 5′-GATCCGTTCGGGGCCCGACGAGGTCGCTGTTGCGTGCTG-3′
oligo6mutcomp 5′-TCGACAGCACGCAACAGCGACCTCGTCGGGCCCCGAACG-3′
Comp: complementary sequence.
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fractions; Sp1 knock-down was assessed byWestern blot and
enhancer activity was assessed by luciferase assay.
SP1 and SP3 combined knock-down
HEK293T cells were co-transfected with siRNA directed
against Sp1 (s8222; Ambion) (15 nM) and Sp3 (s13326,
Ambion) (15 nM) or laminA/C (s58222;Ambion) (30 nM).
Transfections were performed in 24-well plates using Lipo-
fectamine™RNAiMAXTransfectionReagent(Invitrogen)as
per the manufacturer’s instructions and incubated at 37°C
for 24 h before harvesting.
Western blotting
Cell lysates were separated by SDS-polyacrylamide gel elec-
trophoresis (PAGE) using either 4–20% gradient precast
gels (Biorad, Hemel Hempstead, UK) in 1¥ Tris–glycine
SDS (TGS) buffer (Biorad) or Nupage® Novex 3–8% Tris–
acetate precast gels (Invitrogen) in 1¥ Tris–acetate running
buffer (50 mM Trisbase, 50 mM Tricine, 0·4% SDS). Pro-
teins were transferred onto supported nitocellulose (Biorad)
or polyvinylidene diﬂuoride (PVDF) membrane (Biorad),
respectively. Membranes were blocked with 2% milk in
PBS/0·05% Tween-20 overnight and incubated with
primary antibody for 2 h followed by secondary antibodies
conjugated to horseradish peroxidase (HPP) (1:1000–
1:3000 dilution). Chemiluminescent results were obtained
with ECL Plus (Amersham), according to the manufactur-
er’s protocol. Washes were performed with PBS/0·05%
Tween-20. Antibodies used were as follows: anti-Sp1 rabbit
antibody [1:3000; Upstate 07-645, Upstate (Millipore),
Watford, UK], anti-Sp3 D-20 rabbit antibody (1:200; Santa
Cruz SC-644, Santa Cruz, CA, USA), rabbit anti-goat IgG
HRP conjugate (Upstate), anti-alpha-tubulin clone DM1A
mouse antibody (1:10000; Upstate), anti-human MIF goat
antibody (1:300–1:500; R&D Systems, Abingdon, UK),
goat anti-mouse immunoglobulin (Ig)G, HRP conjugate
(Upstate), anti-rabbit IgG HRP (R&D Systems) secondary
antibodies.
Sp1 inhibition assay
CEMC7Aweretreatedwithmithramycin(Sigma)at1 nMto
50 nMfor48 h,thenanalysedbyWesternblottingforendog-
enous MIF production.Alternatively, CEMC7A were treated
with mithramycin at 200 nM for 24 h and transfected tran-
siently with pGL3-control (which possesses an SV40 pro-
moter and an SV40 enhancer), pGL3 promo/oligo-1 and
pGL3. Cell death was analysed using Trypan blue exclusion
(Sigma).
Preparation of nuclear extract
CEMC7A cells were grown to a density of 1 ¥ 10
5 cells/ml in
1 l of RPMI-1640 medium in order to gain a sufﬁcient ﬁnal
volume of nuclear extract. Cells were harvested and washed
twice in PBS.Nuclear extract was then prepared as described
previously [27], with a minor modiﬁcation. Cells were dis-
rupted by passing the cell suspensions through a 23-gauge
needle ﬁve times.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed using a radiolabelled double-
stranded DNA oligonucleotide corresponding to the
intronic oligonucleotide sequence 1 (oligo-1), as described
above.
The annealed oligonucelotide was end-labelled with
[g-
32P]ATP (Amersham) using T4 polynucleotide
kinase (Promega) and puriﬁed using G50 columns
(Amersham).
Reactions contained 10 ml buffer C [10 mM Tris pH 7·8,
50 mM NaCl, 1 mM dithiothreitol (DTT), 1 mM EDTA
5% glycerol], 2 mg bovine serum albumin (BSA),
100 ng poly dI : dC, 0·1 ng labelled probe and 5 mg nuclear
extract, as indicated in the ﬁgure legends. Competition
experiments were performed by adding 100¥ unlabelled
oligonucelotide to the reaction mixes prior to addition of
radiolabelled probe, as indicated. Supershift experiments
were performed by the addition of 2 mg of antibody as
indicated prior to the addition of radiolabelled probe.
Reactions were then incubated at room temperature
for 1 h and loaded onto a 5% 0·5¥ TBE gel run at 150 V
for approximately 3 h. Gels were then dried and
autoradiographed.
Bioinformatics
To compare MIF DNA sequences across species, University
of California Santa Cruz (UCSC) at http://genome.ucsc.edu
and the NCBI at http://www.ncbi.nlm.nih.gov websites were
used. Analysis of MIF intron 1 sequence for potential tran-
scription factor sites was performed using the following
database: AliBaba 2·1 and P-Match at http://www.gene-
regulation.com and MatInspector from Genomatix at http://
www.genomatix.de.
Data analysis
All luciferase results were adjusted to the CMV-renilla
control and calculated as a fold induction relative to the
control promoter. Statistical analysis was performed using
spss version 11·5 or Prism 5. Multiple comparison analysis
wasperformedusingaone-wayanalysisof variance(anova)
withapost-hocBonferronitestandcomparisonof agroupof
data to a control group was performed using a one-way
anova comparative test with a post-hoc two-sided Dunnet’s
t-test.
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DNase I hypersensitivity assay
Nuclei from a total of 10
8 CEMC7A cells were isolated and
treated with increasing amounts of DNase I. The genomic
DNA was then isolated and restriction digested with BglII.
This generated a 10·2 Kb fragment containing 3354 bp 5′ to
the transcriptional start of the MIF gene and 5981 bp 3′ of
the termination codon (Fig. 1b). Hybridization with a
468 bp probe speciﬁc to the 5′ end of the 10·2 Kb fragment
revealed that it was digested by DNase I, indicating the pres-
ence of a hypersensitive site (HS). A shorter fragment of
~3·6 Kb appeared (Fig. 1a) as the DNase I concentration
increased and interpolation of the band height of the
~3·6 Kb fragment indicated the HS spanned ~911 bp
(Fig. 1b). The HS encompassed the ﬁrst intron of MIF,
which was isolated for further study.
The HS acts as an enhancer
The ﬁrst intron of the MIF gene (containing the HS) was
cloned into the pGL3 promoter vector, which contains an
SV40 promoter upstream of the luciferase gene. MIF intron
1 was inserted at a site distal to the SV40 promoter in either
the sense or anti-sense orientation (pGL3 SV40-MIF intron
1 sense/anti-sense). CEMC7A cells were then transfected
with either pGL3 SV40-MIF intron 1 sense/anti-sense plas-
mids, or a pGL3 vector containing the SV40 promoter and
SV40 enhancer (pGL3 SV40-SV40) or the SV40 promoter
only (pGL3-SV40). Constructs were transfected transiently
in CEMC7A cells, and luciferase gene expression was
measured. The intron exhibited orientation-independent
enhancer activity, showing a ﬁvefold increase over the pGL3
promoter-only vector (P < 0·0001) (Fig. 2a).
The enhancer acts in a cell type-speciﬁc manner
In order to determine any cell type-speciﬁcity of intronic
enhancer activity, HEK293T, SW982 (FLS), human RA FLS
and THP-1 cells were transfected with constructs containing
intron 1 of the MIF gene,in which luciferase gene transcrip-
tion is initiated at the SV40 promoter. Enhancer activity was
observed within the CEMC7A cells, as shown previously
(Fig. 2a),with a ﬁvefold induction above the SV40 promoter
control (P < 0·01) (Fig. 2b). Enhanced transcriptional activ-
ity was also observed in HEK293T cells, with a sevenfold
induction over the SV40 promoter (P < 0·0001) (Fig. 2b).
However, no enhancer activity was noted in the FLS cell line
SW982 and cultured RA FLS (Fig. 2b).
To assess if the intron had enhancer activity on the MIF
promoter, the SV40 promoter was substituted for the full-
length MIF promoter -1075 to +85 (CATT5) described pre-
viously [20]. The MIF promoter construct showed similar
levels of transcriptional activation as the SV40 promoter
control and this was consistent with all cell lines (Fig. 2b),
with the exception of the THP-1 cell line, where enhanced
transcriptional activity was detected when the MIF enhancer
was coupled the MIF promoter (P < 0·05) but not with the
SV40 promoter (Fig. 2b). This demonstrated that the intron
could enhance the transcriptional activity of both a heter-
ologouspromoterortheMIFpromoterinacelltype-speciﬁc
manner,with a preference for the MIF promoter in THP-1 s,
where no enhancer activity was detected with the SV40 pro-
moter (Fig. 2b).
Mutation of Sp1 binding site abrogated
enhancer activity
Comparative genomics combined with TF database analysis
were used in order to identify potential TF for the enhancer
DNase I (μg/ml)
DNase I HS
DNase I HS
SLC2A11
–794 CATT5+7 –173 G/C
Exon 1
+1
Exon 2
846 bp
Exon 3
Bgl II Bgl II Bgl II
MIF Probe
0 0·3
10·2 kb
10·2 kb
3·6 kb
3·6 kb
Fragment of interest
MIF gene
(b)
(a) 1 3 10 30
Fig. 1. Mapping of the DNase I hypersensitive site. (a) Genomic DNA
was migrated overnight in a 0·8% agarose gel then transferred to a
nylon membrane and hybridized overnight with a probe speciﬁc for
the 10·2 Kb fragment of interest. Results are representative of two
independent experiments. (b) Interpolation of hypersensitive site
(HS) in untreated CEMC7A cells. The hypersensitive site spans ~911
base pairs but is centred on the ﬁrst intron.
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high density of Sp1 binding sites in the 5′ region of the MIF
intron 1 (Fig. 3a).In order to determine a role for Sp1 in the
enhancer activity of the HS, we cloned seven oligonucle-
otides of ~50 bp each, spanning the full length of the HS, at
the enhancer site of the luciferase reporter vector pGL3,
under the SV40 promoter, to determine the cis-acting ele-
ments in the enhancer (Fig. 3a). The reporter constructs
were assayed in CEMC7A cells and oligo-1 and oligo-6 were
shown to carry the cis elements responsible for the enhancer
activity, as fold induction of luciferase activity over SV40-
only control was increased signiﬁcantly (oligo-1 P < 0·001,
oligo-6 P < 0·05) (Fig. 3b). Oligos-2, -3, -4, -5 and -7 had no
luciferase activity greater than that of the control (data not
shown). Consensus binding site for Sp1 in oligo-1 and
oligo-6weremutatedinordertodisruptSp1bindingandthe
enhanceractivitywasassayedaspertheWToligonucleotides
in CEMC7A cells (Fig. 3c). Disruption of the Sp1 consensus
binding site in both oligo-1 and oligo-6 abrogated enhancer
activity (oligo-1mut P < 0·001, oligo-6mut P < 0·01)
(Fig. 3b), further suggesting a role for Sp1, or its family
members, in driving the HS enhancer activity.
Sp1 binds the MIF enhancer
In order to determine whether Sp1 is recruited to the MIF
intron 1 enhancer, EMSA was performed using CEMC7A
nuclear extract and a radiolabelled DNA probe of the 5′
region of the intronic sequence (oligo-1). We were able to
demonstrate that Sp1 bound this sequence, as competition
with excess cold Sp1 consensus sequence and addition of
Sp1-speciﬁc antibody (aSP1) resulted in the abrogation of a
shifted complex (Fig. 4). The 3′ region of the intron also
possessed putative Sp1 binding sites (oligo-6); however, no
transcription factor binding to this sequence was observed
using the same method (data not shown).
Knock-down of Sp1/Sp3 has no effect on
enhancer activity
The presence of Sp1 in the different cell types in which the
enhancer activity and Sp1 EMSA were studied was deter-
mined using immunoblots of whole cell lysates in untreated
cells. In HEK293T and CEMC7A Sp1 was highly expressed,
whereas THP-1 and FLS cells showed less expression
(Fig. 5a). To analyse further the potential regulatory role of
Sp1 in the enhancer function, RNA interference was used to
depleteSp1inordertoobservewhethertheenhanceractivity
was diminished. Western blotting showed that the endo-
genous Sp1 expression was knocked down in HEK293T cells
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Fig. 2. The DNase I hypersensitive site is a cell type-speciﬁc enhancer.
Reporter assays of the intronic constructs. (a) The ﬁrst intron of the
MIF gene was cloned into the pGL3 promoter vector (SV40) in both
the sense and anti-sense orientation. As a positive control of enhancer
activity the pGL3 control vector was used, which possesses an SV40
enhancer together with the SV40 promoter. The plasmids were
transfected in CEMC7A cells and cells were left to incubate for 24 h
before harvest and luciferase assay. *P < 0·0001. (b) The hypersensitive
site is a cell type-speciﬁc enhancer. The transcriptional activity of the
macrophage migration inhibitory factor (MIF) intron 1 enhancer was
analysed in four different human cell lines: a T lymphoblast cell line
(CEMC7A), an embryonic kidney cell line (HEK293T), a monocytic
cell line (THP-1), a ﬁbroblast-like synoviocyte cell line (FLS) and in
primary ﬁbroblast isolated from rheumatoid arthritis (RA) patients
(RA FLS). Cells were transfected with constructs containing the MIF
intron 1 sequence with either the SV40 promoter or the MIF
promoter initiating luciferase gene expression. Following transfection,
cells were incubated for 24 h before luciferase assays were performed.
Results are representative of a minimum of two independent
experiments ( standard error of the mean) performed in biological
triplicates for all cell lines, and three different patients in biological
duplicates for RA FLS. Results are expressed as a fold induction over
the pGL3 SV40 or pGL3 MIF promoter vector. *P < 0·05; **P < 0·01;
***P < 0·001.

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endogenous MIF expression (Fig. 5b).
Sp1 is part of a family of transcription factors (Sp1–Sp4)
which share highly conserved DNA binding domains and
can function co-operatively to regulate transcription of a
multitude of genes [28]. Other members of the Sp1 family
may be important in the control of the enhancer activity.
Both Sp3 and Sp4 share high afﬁnity for Sp1 consensus
binding sites; however, Sp4 is expressed predominantly in
the brain and shows limited expression in other tissues. Sp3
is expressed ubiquitously, therefore HEK293T cells were
co-transfected with siRNA directed against Sp3 and Sp1 or
lamin A/C as a negative control. Cells were harvested 48 h
post-transfection and cell lysates analysed by Western blot-
ting with anti-Sp1, anti-Sp3, anti-MIF and anti-tubulin
antibodies.Both Sp1 and Sp3 showed a clear knock-down in
HEK293T cells treated with Sp1 and Sp3 siRNA compared
with cells treated with lamin siRNA (Fig. 5b,c). The promi-
nent doublet at ~75 kDa (Sp3) was down-regulated mark-
edly by siRNA; a higher molecular weight band (~100 kDa)
is also Sp3-related and is knocked down by the siRNA
(Fig. 5c). However, the knock-down of Sp1 and Sp3 in com-
bination had no effect on endogenous MIF expression
(Fig. 5c).
Mithramycin speciﬁcally inhibits the enhancer activity
In parallel to the Sp1/Sp3 knock-down assay and mutation
analysis of the Sp1 binding sites in the cis-elements, the Sp1
inhibitormithramycinwasusedtoanalysefurthertheroleof
Sp1 on the MIF intronic enhancer. CEMC7A cells were
transfected transiently with luciferase reporter constructs
containing oligo-1 and oligo-6. Following transfection, cells
were incubated with mithramycin at 200 nM for 24 h. The
enhancer activity was signiﬁcantly higher than that of the
control vector (oligo-1 P < 0·01, oligo-6 P < 0·01) and mith-
ramycin completely inhibited the enhancer activity of both
oligo-1 and oligo-6, compared to the control vector (both
P < 0·05) (Fig. 6a).
To investigate whether mithramycin inhibition of the
enhanceractivityinCEMC7AcellsaffectedendogenousMIF
production, CEMC7A cells were incubated with increasing
concentrationsof mithramycinfor48 h.Mithramycininhib-
ited MIF production from very low concentrations of 1 nM
up to 50 nM, as analysed by Western blotting. No signiﬁcant
cell death, as measured by Trypan blue exclusion, was found
to occur over these time-points (Fig. 6b). Finally, a reporter
assay was carried out in CEMC7A cells to assess speciﬁcity of
the action of mithramycin to the intronic enhancer element
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Fig. 3. Mutation of Sp1 binding sites on cis-acting elements abrogates enhancer activity. (a) Schematic representation of the migration inhibitory
factor (MIF) intronic enhancer and putative Sp1 binding sites. Seven oligonucleotides spanning the length of the intronic hypersensitive sites (HS)
were cloned into pGL3 promoter. The hashed areas represent highly conserved Sp1 transcription factor binding sites. (b) Oligo-1 and oligo-6 are
responsible for MIF enhancer activity. Cells were transfected with constructs containing wild-type (WT) or mutated oligo-1 or oligo-6 sequences.
The pGL3 SV40 promoter-only construct was used as control and results are expressed as fold induction over the control. Following transfection,
cells were incubated for 24 h before luciferase assays were performed. Results are representative of four to 10 independent experiments (standard
error of the mean) performed in single replicates. Results are expressed as a fold induction over the pGL3 SV40 or pGL3 MIF promoter vector.
*P < 0·05; **P < 0·01; ***P < 0·001. (c) Sp1 binding site mutation. Three base pairs in each Sp1 consensus binding site were mutated from G to T,
disrupting the core element for Sp1 binding.
E. Beaulieu et al.
184 © 2010 The Authors
Clinical and Experimental Immunology © 2010 British Society for Immunology, Clinical and Experimental Immunology, 163: 178–188(Fig. 6c). No inhibition of the MIF promoter was detected
after treating cells with 200 nM mithramycin for 24 h, indi-
cating that the inhibitory effect of mithramycin on MIF
endogenousproductionisspeciﬁctoitscapacitytoblockthe
enhancer activity in this cell line.
Discussion
This study aimed to expand the understanding of MIF gene
regulation in cell types of relevance to inﬂammatory
pathologies such as RA.
DNase I treatment revealed a strong HS centred on the
ﬁrst intron of MIF. The intronic constructs examined
showed strong enhancer activity in the CEMC7A cells,
regardless of orientation,suggesting classical enhancer activ-
ity [29,30]. This enhancer was cell type-speciﬁc, with
enhancer activity observed in immune cells,namelyaTl ym -
phoblast and a monocytic cell line, but not in cells from
mesenchymal origin (SW982 and cultured RA FLS), poten-
CEM NE
←  Sp1 specific
–+ +++
Rabbit lgG
100x Cold Sp1
100x Oligo1
Oligo 1
αSP1
Fig. 4. Sp1 binds MIF intron 1. Electrophoretic mobility shift assay
(EMSA) analysis demonstrating the binding of Sp1 to oligo-1. Nuclear
extracts prepared from CEMC7A cells were incubated with
radiolabelled oligo-1. Competition experiments were performed by
the addition of 100¥ unlabelled oligonucleotide (cold Sp1) as
indicated; 2 mg of rabbit IgG or Sp1 antibody added as indicated.
Complexes were then resolved by native gel electrophoresis. Sp1
sequence speciﬁc complex marked by an arrow.

Fig. 5. Neither Sp1 alone nor Sp1/Sp3 combined knock-down effects
the enhancer activity. (a) Endogenous levels of Sp1 protein in
different cell lines. Cell lysates of CEMC7A, FLS, THP-1 and
HEK293T cells were immunoblotted for Sp1, alpha-tubulin and
migration inhibitory factor (MIF). Results are representative of a
minimum of two independent experiments performed in biological
triplicates. (b) A pool of four siRNA sequences directed against Sp1 or
Lamin A/C (negative control), 100 nM siRNA and 1–5 mg plasmid
DNA were used per reaction. Transfected cells were incubated for 48 h
Sp1 knock-down and endogenous MIF production was assessed by
Western blotting. No down-regulation of the MIF protein was seen on
endogenous MIF expression in HEK293T. (c) SiRNA directed against
Sp1 (15 nM) and Sp3 (15 nM) or lamin A/C (negative control)
(30 nM) were co-transfected into HEK293T cells. Cells were harvested
48 h post-transfection and subject to Western blot analysis with
anti-Sp1, anti-Sp3, anti-MIF and anti-a-tubulin antibodies as
indicated.
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expression in immune cells.
Database searches for transcription factor binding sites
(TFBS) showed highly conserved Sp1 sites within oligo-1
and oligo-6 sequences. Sp1 is part of a large family of tran-
scription factors which bind similar consensus sequences,
although they have highly diverse functions (reviewed in
[31,32]). Sp1 drives the expression of several constitutive
genesandtheSp1nullmousediesatday11of gestation[33].
We therefore focused initially on Sp1 as the candidate TF
mediating the enhancer activity. First, we used mutation
analysis of the Sp1 binding site in oligo-1 and oligo-6. Dis-
ruption of the Sp1 consensus binding sites completely abro-
gated the enhancer activity in both oligonucleotides,
demonstrating the crucial function of these sequences and
suggesting Sp1 is the TF driving the enhancer activity. Sec-
ondly, we used EMSA to determine Sp1 binding to cis-
elements present in the HS site that were shown to have
enhancer activity. We determined that oligo-1 was able to
bind Sp1 present in CEMC7A nuclear extracts by competi-
tionwithunlabelledSp1consensussequenceandincubation
with Sp1-speciﬁc antibody. This further supported Sp1 as
the TF responsible the enhancer activity of the HS site.
Sp1 is expressed ubiquitously in most cell types,but levels
of expression may differ from one cell type to another and
inﬂuencetheactivityof theTF.Welookedattheendogenous
expression of Sp1 in the several cell types where we had
observed the HS site to have an enhancer activity. Sp1 was
expressed at higher levels in both CEMC7A and HEK293T
cells, which was concordant with the highest level of
enhancer activity of the HS site in these cells.
We used reverse genetics and depleted HEK293T cells,
which had the highest level of Sp1 expression, of Sp1 and of
Sp3 using small interfering RNA (siRNA). The enhancer
activity was not changed when Sp1 was knocked down alone
or in combination with Sp3, and there was no effect on MIF
protein production.Multiple isoforms are known to exist for
Sp3 (UniProtKB/Swiss-Prot Q0227), and two were observed
in the HEK293T cells. Furthermore, due to the high endog-
enouslevelsof Sp1inthesecells,itispossiblethatasufﬁcient
concentration of Sp1 remained for it to bind effectively to
the MIF intronic enhancer.
Mithramycin(orplicamycin)isanaureolicacidwhichhas
been used in the treatment of cancer and hypercalcaemia
[34,35], and has been used in many studies of the Sp family
[36–40]. Mithramycin speciﬁcally abrogated the enhancer
activity for both cis-acting elements of the ﬁrst intron of
MIF, without having any effect on the MIF promoter vector
in CEMC7A cells. This suggests that the GC-rich elements
within oligo-1 and oligo-6 are the core enhancer elements.
Mithramycin binds GC boxes as opposed to speciﬁcally
inhibiting Sp1 binding to DNA [37,41]. The Sp family pos-
sesses eight members; Sp1–Sp4 have similar structures and
Sp5–Sp8 also have similar structures, but appear to be trun-
cated forms of Sp1– Sp4 (reviewed in [32]). Co-operation
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Fig. 6. Mithramycin speciﬁcally inhibits the enhancer activity and
endogenous migration inhibitory factor (MIF) expression. (a)
Mithramycin inhibits the enhancer activity in CEMC7A cells.
CEMC7A cells were transfected transiently either with a control
vector possessing the SV40 promoter (control) or a vector containing
oligo-1 or oligo-6. The cells were then treated with 200 nM
mithramycin and left to incubate for 24 h. In untreated cells (white
columns), the oligo-1 and oligo-6 reporter assays show enhancer
activity. This activity was abrogated by the addition of mithramycin to
the cells (black columns). Results are representative of a minimum of
two independent experiments (standard error of the mean)
performed in biological triplicates. Results are expressed in fold
induction over the untreated control vector. *P < 0·05; **P < 0·01. (b)
Mithramycin inhibits endogenous expression of MIF in CEMC7A
cells. CEMC7A cells were treated with increasing amounts of
mithramycin (0, 1, 10 and 50 nM) for 24 h. Cell lysates were then
collected and immunoblotted with the relevant primary anti-sera:
anti-MIF goat antibody for MIF and anti-alpha-tubulin clone DM1A
mouse antibody for tubulin. Cell death was counted by trypan blue
exclusion. Results are representative of three independent experiments
peformed in biological triplicates. (c) Mithramycin has no effect on
the MIF promoter. CEMC7A cell were transfected with the MIF
promoter only plasmid (MIF promo) and were left untreated (white
column) or were treated with 200 nM mithramycin (black column)
and left to incubate 24 h before luciferase assay was performed.
Results are representative of two independent experiments performed
in biological triplicates. Results are expressed in fold induction over
untreated cells.
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been described previously [42,43], and as such these remain
possible interaction partners for Sp1 and could inﬂuence
MIF enhancer function.
To determine the physiological relevance of the enhancer,
CEMC7A cells were treated with increasing concentrations
of mithramycin, and comparison of MIF protein expression
between treated and untreated cells was undertaken.Clearly,
endogenous MIF production was inhibited after treating
CEMC7A cells with 10 nM of mithramycin for 48 h (Fig. 5).
Importantly, the inhibitory effect of mithramycin on MIF
production was speciﬁc to the enhancer activity, as mithra-
mycin had no effect on the MIF promoter itself, despite its
high GC content, and the presence of a number of putative
Sp1 sites.
Roger et al. found that mithramycin inhibited the tran-
scriptional activity of a MIF promoter reporter assay and
MIF mRNA expression in monocytic THP-1 cells [44]. We
have looked at the effects of mithramycin in a different cell
type, a T lymphoblastic cell line, CEMC7A, and found no
effectof mithramycinontheMIFpromoterbutinhibitionof
the MIF intronic enhancer. These observations show that
mithramycin, albeit potentially through different mecha-
nisms,playsanimmunosuppressiveroleonimmunecellsvia
the down-regulation of MIF.
As an anti-neoplastic drug, the role of mithramycin in
apoptosis [45] and in inﬂammation has been investigated
previously [46].Mithramycin has also been shown to inhibit
bone resorption [47]. Analogues of mithramycin have been
developed recently which have enhanced efﬁcacy and speci-
ﬁcity [48,49].Use of such drugs for the selective reduction of
MIF in circulating immune cells could enhance the thera-
peutic advantage of glucocorticoids, which has important
implications in the long-term management of chronic
inﬂammatory conditions such as RA.
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